CA2024-LM-001NCT07098806
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
At risk: Primary completion moved at least 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Oct 2, 2026 to Jul 31, 2027
- Eligibility criteria expanded, about 26 words
- Secondary endpoints: details revised at 2 of 5 entries
- Notable Phase changed: Phase 1 → Phase 1/2
- Sponsor changed: Plus Therapeutics to Cerenome
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Maximum Tolerated Dose
Timeframe: 13 months
Dose Distribution of 186RNL
Timeframe: 13 months
Safety and tolerability of multiple dose treatment
Timeframe: 13 months
Secondary (5)
Determine the objective response rate (ORR).
Determine the overall survival (OS).
Characterize the dosimetry profile of 186RNL.
Determine neurologic progression-free survival (PFS).
Evaluate Neurologic status by NANO scale
Arms and interventions
Experimental: Multiple DosesExperimental
This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.
Drugs: 186RNL
Sites
1 site in 1 country
- The Cancer Therapy and Research Center at UTHSCSASan Antonio, Texas, United States